Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
Sánchez-Martín FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Cañadas I, Vidal J, Martinez A, Argilés G, Siravegna G, Arena S, Koefoed K, Visa L, Arpí O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Tabernero J, Bardelli A, Montagut C. Sánchez-Martín FJ, et al. Clin Cancer Res. 2016 Jul 1;22(13):3260-7. doi: 10.1158/1078-0432.CCR-15-2400. Epub 2016 Feb 17. Clin Cancer Res. 2016. PMID: 26888827
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
Xiong W, Friese-Hamim M, Johne A, Stroh C, Klevesath M, Falchook GS, Hong DS, Girard P, El Bawab S. Xiong W, et al. CPT Pharmacometrics Syst Pharmacol. 2021 May;10(5):428-440. doi: 10.1002/psp4.12602. Epub 2021 May 1. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33818908 Free PMC article.
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Paik PK, et al. N Engl J Med. 2020 Sep 3;383(10):931-943. doi: 10.1056/NEJMoa2004407. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469185 Free PMC article. Clinical Trial.
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Licitra L, Mesia R, Rivera F, Remenár É, Hitt R, Erfán J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, Störkel S, Senger S, Stroh C, Vermorken JB. Licitra L, et al. Ann Oncol. 2011 May;22(5):1078-1087. doi: 10.1093/annonc/mdq588. Epub 2010 Nov 3. Ann Oncol. 2011. PMID: 21048039 Free PMC article. Clinical Trial.
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.
Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, Macarulla T, Rodriguez-Braun E, Eugenia Vega-Villegas M, Senger S, Ramos FJ, Roselló S, Celik I, Stroh C, Baselga J, Ciardiello F. Tabernero J, et al. J Clin Oncol. 2010 Mar 1;28(7):1181-9. doi: 10.1200/JCO.2009.22.6043. Epub 2010 Jan 25. J Clin Oncol. 2010. PMID: 20100964 Clinical Trial.
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping.
Le X, Hong L, Hensel C, Chen R, Kemp H, Coleman N, Ciunci CA, Liu SV, Negrao MV, Yen J, Xia X, Scheuenpflug J, Stroh C, Juraeva D, Tsao A, Hong D, Raymond V, Paik P, Zhang J, Heymach JV. Le X, et al. Among authors: stroh c. JCO Precis Oncol. 2021 Dec 13;5:PO.21.00135. doi: 10.1200/PO.21.00135. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34957368 Free PMC article.
34 results